Dominik F Draxler, Kah Yep, Gryselda Hanafi, Anoushka Winton, Maria Daglas, Heidi Ho, Maithili Sashindranath, Lisa M Wutzlhofer, Andrew Forbes, Isaac Goncalves, Huyen A Tran, Sophia Wallace, Magdalena Plebanski, Paul S Myles, Robert L Medcalf
Tranexamic acid (TXA) is an antifibrinolytic agent that blocks plasmin formation. Because plasmin is known to promote inflammatory and immunosuppressive responses, we explored the possibility that plasmin-mediated immunosuppression in patients undergoing cardiac surgery can be directly reversed by TXA and decrease postoperative infection rates. The modulatory effect of TXA on inflammatory cytokine levels and on innate immune cell activation were evaluated with multiplex enzyme-linked immunosorbent assay and flow cytometry, respectively...
May 28, 2019: Blood Advances